Leidos Biomedical Research, Inc.
Frederick National Laboratory for Cancer Research
P.O. Box B, 8560 Progress Drive
About Leidos Biomedical Research, Inc.
Leidos Biomedical Research, Inc. operates the Frederick National Laboratory for Cancer Research under contract to the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services.
The national lab partners with university, corporate, and government scientists to accelerate research discoveries, develop new technologies, and move new diagnostics and treatments into the clinic to benefit patients with cancer and AIDS.
As a Federally Funded Research and Development Center, the national lab excels at innovation and flexibility of operations, offering scientific depth, cutting-edge technologies, and enabling infrastructure. It is one of about 40 U.S. national laboratories and the only one in the nation devoted exclusively to biomedical research.
View jobs from this company
41 articles with Leidos Biomedical Research, Inc.
Leidos announced today that Jason Albanese has been named the Leidos Health Group's senior vice president of business development.
Combined Technologies May Yield Therapies for Multiple Cancer Indications
9/5/2018Summer is coming to an end, but the job front is still sizzling. Check out the top companies who are looking for candidates like you right now!
The United States Department of Energy has awarded the team of Leidos and Battelle a $364.7 million Research Support Services (RSS) contract at the National Energy Technology Laboratory (NETL).
Naval Medical Logistics Command Awards Leidos Contract to Study Health Impact of Undersea Operations on Submariners
Leidos was awarded a follow-on contract by the Naval Medical Logistics Command to support biomedical research and development at its Naval Submarine Medical Research Laboratory (NSMRL).
Revenues: $2.53 billion
Cambridge Research Biochemicals to Support Preclinical Study on Treatment for Vision-Damaging Eye Disease
Cambridge Research Biochemicals® will support evaluation of a potential new treatment approach for Fuchs Dystrop.
The follow-on single-award time & materials contract has a one year-base period, four one-year options, and a total contract value of $26M.
The two companies will expands its collaboration to develop preventative, peptide-based malaria vaccine candidates.
Leidos Announces Appointment of Ethan Dmitrovsky, M.D. as President of Leidos Biomedical Research and Laboratory Director of the Frederick National Laboratory for Cancer Research
Leidos announced today that Ethan Dmitrovsky, M.D. was appointed President of subsidiary Leidos Biomed and Laboratory Director of the FNLCR.
PositiveID (PSID) Announces Teaming Agreement With SAIC-Frederick, Inc. to Pursue Defense Threat Reduction Agency Contracts
SAIC-Frederick, Inc. and RemedyMD, Inc. Collaborate to Enhance Research Management Systems in Support of Cancer Research
ApoCell, Inc. Awarded $2.9 Million from SAIC-Frederick, Inc. to Deliver a New Platform for Detection and Molecular Analysis of Circulating Tumor Cells (CTCs) to the National Cancer Institute’s Pharmacodynamics Program